SALT LAKE CITY, UT--(Marketwire - March 03, 2009) - Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the 29h Annual Cowen Health Care Conference, at 4:40 p.m. on March 17, at the Boston Marriott Copley Place in Boston, Massachusetts.
A live audio webcast of this presentation will be available online and can be accessed through a link on Myriad's home page at www.myriad.com.
About Myriad Genetics
Myriad Genetics, Inc. is a leading healthcare company focused on the development and marketing of novel molecular diagnostic and therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, Azixa and Vivecon are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G
This press release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements relating the scheduled presentation of an overview of the
Company at the 29th Annual Cowen Health Care Conference on March 17, 2009.
These forward looking statements are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by forward-looking statements.
These risks and uncertainties include, but are not limited to: the risk
that we may be unable to further identify, develop and achieve commercial
success for new products and technologies; the risk that we may be unable
to discover drugs that are safer and more efficacious than our competitors;
the risk that we may be unable to develop manufacturing capability for
approved products; the risk that sales of our existing molecular diagnostic
products may decline or not continue to increase at historical rates; the
risk that we may be unable to develop additional molecular diagnostic
products that help assess which patients are subject to greater risk of
developing diseases and who would therefore benefit from new preventive
therapies; the possibility of delays in the research and development
necessary to select drug development candidates and delays in clinical
trials; the risk that clinical trials may not result in marketable
products; the risk that we may be unable to successfully finance and secure
regulatory approval of and market our drug candidates, or that clinical
trials will not be completed on the timelines we have estimated;
uncertainties about our ability to obtain new corporate collaborations and
acquire new technologies on satisfactory terms, if at all; the development
of competing products and services; the risk that we may be unable to
protect our proprietary technologies; the risk of patent-infringement
claims; risks of new, changing and competitive technologies and regulations
in the United States and internationally; and other factors discussed under
the heading "Risk Factors" contained in Item 1A in our Annual Report on
Form 10-K for the year ended June 30, 2008, which has been filed with the
Securities and Exchange Commission, as well as any updates to those risk
factors filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K. All information in this press release is as of
the date of the release, and Myriad undertakes no duty to update this
information unless required by law.
